Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gore announces availability of septal occluder:

This article was originally published in Clinica

Executive Summary

W L Gore & Associates forecasts that its HELEX septal occluder device, recently launched in Europe, Australia and South America, could gain US marketing approval in around three years. The device, which is being studied under an investigational device exemption, has "significant advantages over [current]-devices", claims the Flagstaff, Arizona firm. When fully deployed, it takes on a double disc, rounded shape that minimises the risk of trauma to cardiac structures. It also incorporates a retrieval cord system that allows the device to be removed, even after it has been released from the catheter delivery system.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT071548

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel